A subtype of multiple sclerosis defined by an activated immune defense program

Given the heterogeneous nature of multiple sclerosis (MS), we applied DNA microarray technology to determine whether variability is reflected in peripheral blood (PB) cells. In this study, we studied whole-blood gene expression profiles of 29 patients with relapsing-remitting MS (RRMS) and 25 age- and sex-matched healthy controls. We used microarrays with a complexity of 43K cDNAs. The data were analyzed using sophisticated pathway-level analysis in order to provide insight into the deregulated peripheral immune response programs in MS. We found a remarkable elevated expression of a spectrum of genes known to be involved in immune defense in the PB of MS patients compared to healthy individuals. Cluster analysis revealed that the increased expression of these genes was characteristic for approximately half of the patients. In addition, the gene signature in this group of patients was comparable with a virus response program. We conclude that the transcriptional signature of the PB cells reflects the heterogeneity of MS and defines a sub-population of RRMS patients, who exhibit an activated immune defense program that resembles a virus response program, which is supportive for a link between viruses and MS.

[1]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[2]  D. Hafler.  Multiple sclerosis. , 2004, The Journal of clinical investigation.

[3]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Bajramovic,et al.  Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis , 2000, Journal of Neuroimmunology.

[5]  Mark R. Player,et al.  The 2–5 A system: Modulation of viral and cellular processes through acceleration of RNA degradation , 1998, Pharmacology & Therapeutics.

[6]  P. Staeheli,et al.  Function of the mouse Mx1 protein is inhibited by overexpression of the PB2 protein of influenza virus. , 1993, Virology.

[7]  G. Pinkus,et al.  Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis , 2005 .

[8]  Steven A Greenberg,et al.  Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. , 2005, Annals of neurology.

[9]  Ec Beachler.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003 .

[10]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[11]  Å. Lernmark,et al.  Interferon Expression in the Pancreases of Patients With Type I Diabetes , 1995, Diabetes.

[12]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[13]  Murali Ramanathan,et al.  Genomic effects of IFN-beta in multiple sclerosis patients. , 2003, Journal of immunology.

[14]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[15]  R. Holmdahl,et al.  Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Nir Friedman,et al.  Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity , 2004, Annals of neurology.

[17]  G. Cutter,et al.  MRI as a marker for disease heterogeneity in multiple sclerosis , 2005, Neurology.

[18]  R K Craig,et al.  Methods in molecular medicine. , 1987, British medical journal.

[19]  Richard A. Young,et al.  Insights into host responses against pathogens from transcriptional profiling , 2005, Nature Reviews Microbiology.

[20]  D. Paty,et al.  A population‐based study of multiple sclerosis in twins: Update , 1993 .

[21]  D. Hober,et al.  Increased levels of antiviral MxA protein in peripheral blood of patients with A chronic disease of unknown etiology * , 2001, Journal of medical virology.

[22]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Sturfelt,et al.  Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies , 2000, Lupus.

[24]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[26]  G. Kochs,et al.  Missorting of LaCrosse Virus Nucleocapsid Protein by the Interferon‐Induced MxA GTPase Involves Smooth ER Membranes , 2004, Traffic.

[27]  Adeline R. Whitney,et al.  The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Satoh,et al.  Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis , 2005, Neurobiology of Disease.

[29]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[30]  L. Greller,et al.  Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods , 2004, PLoS biology.

[31]  T. Dermody,et al.  Role of oxidative damage in the pathogenesis of viral infections of the nervous system. , 2005, Histology and histopathology.

[32]  G. Rosati,et al.  The worldwide prevalence of multiple sclerosis , 2002, Clinical Neurology and Neurosurgery.

[33]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[34]  Hiroaki Kitano,et al.  The PANTHER database of protein families, subfamilies, functions and pathways , 2004, Nucleic Acids Res..

[35]  T Kuner,et al.  Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. , 1994, Science.

[36]  J. Satoh,et al.  Microarray analysis identifies interferon β-regulated genes in multiple sclerosis , 2003, Journal of Neuroimmunology.

[37]  J. Eberwine,et al.  Amplified RNA synthesized from limited quantities of heterogeneous cDNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Achiron,et al.  Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus , 2004, Clinical and experimental immunology.

[39]  Gavin Sherlock,et al.  The Stanford Microarray Database accommodates additional microarray platforms and data formats , 2004, Nucleic Acids Res..

[40]  R. J. Cho,et al.  Transcription, genomes, function. , 2000, Trends in genetics : TIG.

[41]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[42]  L. Rönnblom,et al.  Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. , 2005, Arthritis and rheumatism.

[43]  Thomas M. Aune,et al.  Cutting Edge: Molecular Portrait of Human Autoimmune Disease1 , 2002, The Journal of Immunology.

[44]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[45]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[46]  C. Wijbrandts,et al.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.

[47]  C. Samuel,et al.  Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. , 1995, Virology.

[48]  J. Kurtzke,et al.  Epidemiology of MS , 1991, Neurology.

[49]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Jason H. Moore,et al.  Gene expression profiles in human autoimmune disease. , 2003, Current pharmaceutical design.

[51]  Murali Ramanathan,et al.  Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.

[52]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Moynagh.  TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. , 2005, Trends in immunology.

[54]  Gene expression profiling in rheumatology. , 2007, Methods in molecular medicine.

[55]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.